Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Ramalingam

Showing results (281-290 of 502) with videos related to

Pageof 51
Sort By:
The Journal of Clinical Investigation|November 15, 2022
mTOR regulates T cell exhaustion and PD-1-targeted immunotherapy response during chronic viral infectionSatomi Ando, Charles M Perkins, Yamato Sajiki, et al.
Cancer Research|October 31, 2019
Mcl-1 Interacts with Akt to Promote Lung Cancer ProgressionGuo Chen, Dongkyoo Park, Andrew T Magis, et al.
Cancer|June 30, 2011
Human immunodeficiency virus-associated lung cancer in the era of highly active antiretroviral therapySuchita Pakkala, Zhengjia Chen, David Rimland, et al.
Investigational New Drugs|August 4, 2010
A phase 1 study of BMS-275183, a novel oral analogue of paclitaxel given on a daily schedule to patients with advanced malignanciesElisabeth I Heath, Patricia Lorusso, Suresh S Ramalingam, et al.
Cancer|September 9, 2020
Efficacy and safety of immune checkpoint blockade in self-identified Black patients with advanced non-small cell lung cancerBassel Nazha, Subir Goyal, Zhengjia Chen, et al.
The Journal of Clinical Investigation|February 16, 2026
Cotargeting DNA topoisomerase II enhances efficacy of RAS-targeted therapy in KRAS-mutant cancer modelsRongzhong Xu, Dongsheng Wang, Guangzhi Ma, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 26, 2009
Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancerSuresh S Ramalingam, Michael L Maitland, Paul Frankel, et al.
Clinical Pharmacology and Therapeutics|August 14, 2009
Pharmacokinetic study of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignanciesW C Zamboni, S Strychor, L Maruca, et al.
Cancer Research|July 22, 2021
Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, OsimertinibLei Zhu, Zhen Chen, Hongjing Zang, et al.
Cancer Letters|July 25, 2016
Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatmentPuyu Shi, You-Take Oh, Guojing Zhang, et al.
Pageof 51

Showing results (281-290 of 502) with videos related to

Sort By:
Pageof 51
The Journal of Clinical Investigation|November 15, 2022
mTOR regulates T cell exhaustion and PD-1-targeted immunotherapy response during chronic viral infectionSatomi Ando, Charles M Perkins, Yamato Sajiki, et al.
Cancer Research|October 31, 2019
Mcl-1 Interacts with Akt to Promote Lung Cancer ProgressionGuo Chen, Dongkyoo Park, Andrew T Magis, et al.
Cancer|June 30, 2011
Human immunodeficiency virus-associated lung cancer in the era of highly active antiretroviral therapySuchita Pakkala, Zhengjia Chen, David Rimland, et al.
Investigational New Drugs|August 4, 2010
A phase 1 study of BMS-275183, a novel oral analogue of paclitaxel given on a daily schedule to patients with advanced malignanciesElisabeth I Heath, Patricia Lorusso, Suresh S Ramalingam, et al.
Cancer|September 9, 2020
Efficacy and safety of immune checkpoint blockade in self-identified Black patients with advanced non-small cell lung cancerBassel Nazha, Subir Goyal, Zhengjia Chen, et al.
The Journal of Clinical Investigation|February 16, 2026
Cotargeting DNA topoisomerase II enhances efficacy of RAS-targeted therapy in KRAS-mutant cancer modelsRongzhong Xu, Dongsheng Wang, Guangzhi Ma, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 26, 2009
Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancerSuresh S Ramalingam, Michael L Maitland, Paul Frankel, et al.
Clinical Pharmacology and Therapeutics|August 14, 2009
Pharmacokinetic study of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignanciesW C Zamboni, S Strychor, L Maruca, et al.
Cancer Research|July 22, 2021
Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, OsimertinibLei Zhu, Zhen Chen, Hongjing Zang, et al.
Cancer Letters|July 25, 2016
Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatmentPuyu Shi, You-Take Oh, Guojing Zhang, et al.
Pageof 51